The hormone insulin plays a central role in the metabolism of many living organisms. When food is plentiful, insulin promotes ...

Research has shed light on the intricate mechanisms of insulin production in fruit flies, revealing surprising parallels with ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in ...

How does the body regulate the activity of insulin-producing cells in order to react quickly to changing conditions? Researchers have investigated this question.

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...

reducing food intake and having trophic effects on the pancreatic islet cells. [9] These incretin hormones have been implicated recently in the pathogenesis of Type 2 diabetes. GLP-1 is ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.